Celldex Therapeutics Share Holder Equity 2010-2022 | CLDX
Celldex Therapeutics share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Celldex Therapeutics Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$419 |
| 2020 |
$209 |
| 2019 |
$94 |
| 2018 |
$124 |
| 2017 |
$236 |
| 2016 |
$265 |
| 2015 |
$290 |
| 2014 |
$212 |
| 2013 |
$320 |
| 2012 |
$96 |
| 2011 |
$69 |
| 2010 |
$75 |
| 2009 |
$74 |
Celldex Therapeutics Quarterly Share Holder Equity
(Millions of US $) |
| 2022-03-31 |
$398 |
| 2021-12-31 |
$419 |
| 2021-09-30 |
$437 |
| 2021-06-30 |
$182 |
| 2021-03-31 |
$194 |
| 2020-12-31 |
$209 |
| 2020-09-30 |
$230 |
| 2020-06-30 |
$238 |
| 2020-03-31 |
$84 |
| 2019-12-31 |
$94 |
| 2019-09-30 |
$101 |
| 2019-06-30 |
$110 |
| 2019-03-31 |
$113 |
| 2018-12-31 |
$124 |
| 2018-09-30 |
$128 |
| 2018-06-30 |
$128 |
| 2018-03-31 |
$134 |
| 2017-12-31 |
$236 |
| 2017-09-30 |
$219 |
| 2017-06-30 |
$231 |
| 2017-03-31 |
$248 |
| 2016-12-31 |
$265 |
| 2016-09-30 |
$217 |
| 2016-06-30 |
$235 |
| 2016-03-31 |
$260 |
| 2015-12-31 |
$290 |
| 2015-09-30 |
$319 |
| 2015-06-30 |
$346 |
| 2015-03-31 |
$376 |
| 2014-12-31 |
$212 |
| 2014-09-30 |
$239 |
| 2014-06-30 |
$265 |
| 2014-03-31 |
$292 |
| 2013-12-31 |
$320 |
| 2013-09-30 |
$157 |
| 2013-06-30 |
$177 |
| 2013-03-31 |
$195 |
| 2012-12-31 |
$96 |
| 2012-09-30 |
$91 |
| 2012-06-30 |
$95 |
| 2012-03-31 |
$108 |
| 2011-12-31 |
$69 |
| 2011-09-30 |
$81 |
| 2011-06-30 |
$92 |
| 2011-03-31 |
$66 |
| 2010-12-31 |
$75 |
| 2010-09-30 |
$52 |
| 2010-06-30 |
$60 |
| 2010-03-31 |
$68 |
| 2009-12-31 |
$74 |
| 2009-09-30 |
$-2 |
| 2009-06-30 |
$4 |
| 2009-03-31 |
$12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.061B |
$0.005B |
|
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
|
